Risk factors for recurrence in patients with Staphylococcus aureus infections complicated by bacteremia
- PMID: 16631340
- DOI: 10.1016/j.diagmicrobio.2006.01.021
Risk factors for recurrence in patients with Staphylococcus aureus infections complicated by bacteremia
Abstract
Recurrence is a common complication of Staphylococcus aureus infections. A shorter duration of antibiotic treatment for a S. aureus infection has been previously suggested as a possible risk factor for recurrence. We conducted a retrospective cohort study of patients with S. aureus infection complicated by bacteremia who survived their initial treatment (N = 397) at the VA Maryland Health Care System from 1995 to 2004 to determine if 2 weeks or less of antibiotic therapy is significantly associated with a higher rate of recurrence. Recurrence was defined as recurrence of infection because of S. aureus with the same susceptibility to methicillin within 1 year of treatment of the initial bacteremia. Seventeen percent of patients who survived their initial infection had a recurrence of infection. Mean duration of antibiotic therapy in those who recurred was longer than in those who did not recur (21 versus 18 days, P = .18). No evidence was found to support an association between a duration of therapy of 14 days or less and an increased risk for recurrence (RR, 0.68; 95% CI, 0.44-1.04). However, being HIV infected (OR, 4.59; 95% CI, 1.61-13.10), having diabetes (OR, 2.02; 95% CI, 1.13-3.61) and having an infection due to a methicillin-resistant S. aureus (MRSA) (OR, 2.11; 95% CI, 1.17-3.80) were independent risk factors for recurrence. In conclusion, 2 weeks or less of antibiotic therapy was not associated with an increased risk for recurrence. However, patients with diabetes or HIV infection and patients with MRSA infections are at an increased risk for recurrence and should be followed more closely.
Similar articles
-
Staphylococcus aureus bacteremia: recurrence and the impact of antibiotic treatment in a prospective multicenter study.Medicine (Baltimore). 2003 Sep;82(5):333-9. doi: 10.1097/01.md.0000091184.93122.09. Medicine (Baltimore). 2003. PMID: 14530782
-
Staphylococcus aureus bloodstream infections: risk factors, outcomes, and the influence of methicillin resistance in Calgary, Canada, 2000-2006.J Infect Dis. 2008 Aug 1;198(3):336-43. doi: 10.1086/589717. J Infect Dis. 2008. PMID: 18522502
-
Comparison of both clinical features and mortality risk associated with bacteremia due to community-acquired methicillin-resistant Staphylococcus aureus and methicillin-susceptible S. aureus.Clin Infect Dis. 2008 Mar 15;46(6):799-806. doi: 10.1086/527389. Clin Infect Dis. 2008. PMID: 18266610
-
Management of methicillin-resistant Staphylococcus aureus bacteremia.Clin Infect Dis. 2008 Jun 1;46 Suppl 5:S386-93. doi: 10.1086/533595. Clin Infect Dis. 2008. PMID: 18462094 Review.
-
Staphylococcus aureus bloodstream infections: definitions and treatment.Clin Infect Dis. 2009 May 15;48 Suppl 4:S254-9. doi: 10.1086/598186. Clin Infect Dis. 2009. PMID: 19374581 Review.
Cited by
-
Surveillance and management of all types of Staphylococcus aureus bacteraemia.BMJ. 2006 Aug 5;333(7562):269-70. doi: 10.1136/bmj.333.7562.269. BMJ. 2006. PMID: 16888291 Free PMC article. No abstract available.
-
Plasma Cell-Free DNA Next-Generation Sequencing to Diagnose and Monitor Infections in Allogeneic Hematopoietic Stem Cell Transplant Patients.Open Forum Infect Dis. 2018 Nov 16;5(12):ofy301. doi: 10.1093/ofid/ofy301. eCollection 2018 Dec. Open Forum Infect Dis. 2018. PMID: 30581881 Free PMC article.
-
Combination therapy with an aminoglycoside for Staphylococcus aureus endocarditis and/or persistent bacteremia is associated with a decreased rate of recurrent bacteremia: a cohort study.Infection. 2011 Dec;39(6):549-54. doi: 10.1007/s15010-011-0189-2. Epub 2011 Sep 6. Infection. 2011. PMID: 21898120 Free PMC article.
-
Risk Factors of Recurrent Infection in Patients with Staphylococcus aureus Bacteremia: a Competing Risk Analysis.Antimicrob Agents Chemother. 2022 Jul 19;66(7):e0012622. doi: 10.1128/aac.00126-22. Epub 2022 Jun 28. Antimicrob Agents Chemother. 2022. PMID: 35762799 Free PMC article.
-
Multicenter Cohort Study of Ceftaroline Versus Daptomycin for Treatment of Methicillin-Resistant Staphylococcus aureus Bloodstream Infection.Open Forum Infect Dis. 2021 Dec 23;9(3):ofab606. doi: 10.1093/ofid/ofab606. eCollection 2022 Mar. Open Forum Infect Dis. 2021. PMID: 35146040 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
